CDK4 and breast cancer: Next, we evaluated whether addition of CDK2i (dinaciclib) to the combined CDK4/6i (palbociclib) and AI (letrozole) standard treatment efficiently abrogated growth of letrozole-resistant MCF7-derived BC tumors in vivo.